Download PDF
Klin Monbl Augenheilkd 2022; 239(04): 572-574
DOI: 10.1055/a-1766-6739
Der interessante Fall

Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib

Intermediäre Uveitis bei einem HLA-B27-positiven Patienten, der mit Upadacitinib behandelt wurde
Julie Schneider
1   Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland
,
Ann Schalenbourg
1   Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland
,
Jean Dudler
2   Department of Rheumatology, HFR, Fribourg, Switzerland
,
Yan Guex-Crosier 
1   Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Background

Janus activated kinases (JAKs) are a family of intracellular tyrosine kinases that function as intracellular mediators of multiple cytokines and growth factors involved in the pathogenesis of inflammation and immune-mediated diseases. Many JAK inhibitors (JAKinibs) have been developed over recent years and they have emerged as a new therapeutic class for immune-mediated inflammatory diseases. Tofacitinib (Xeljanz, an anti JAK1-JAK3 agent) and baricitinib (Omlumiant, an anti JAK1-JAK2 agent) are first-generation JAKinibs. Upadacitinib (Rinvoq) is a specific, newer Janus kinase (JAK-1) inhibitor recently approved for the treatment of inflammatory disorders such as rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and psoriatic arthritis [1], [2], [3], [4]. However, few data are available on the use of these recent therapies in the management of ocular inflammation.



Publication History

Received: 26 September 2021

Accepted: 06 February 2022

Article published online:
26 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Van der Heijde D, Song IH, Pangan AL. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108-2117
    CrossrefPubMedGoogle Scholar
  • 2 Smolen JS, Pangan AL, Emery P. et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393: 2303-2311
    CrossrefPubMedGoogle Scholar
  • 3 Mease PJ, Lertratanakul A, Anderson JK. et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2020; 80: 312-320
    CrossrefPubMedGoogle Scholar
  • 4 Guttman-Yassky E, Thaçi D, Pangan AL. et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884
    CrossrefPubMedGoogle Scholar
  • 5 Dodds EM, Lowder CY, Meisler DM. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm 1999; 7: 85-92
    CrossrefPubMedGoogle Scholar
  • 6 Heimann H, Bornfeld N, Vij O. et al. Vasoproliferative tumours of the retina. Br J Ophthalmol 2000; 84: 1162-1169
    CrossrefPubMedGoogle Scholar
  • 7 Bing SJ, Lyu C, Xu B. et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis 2020; 26: 641-651
    PubMedGoogle Scholar
  • 8 Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm 2019; 27: 1232-1234
    CrossrefPubMedGoogle Scholar
  • 9 Paley MA, Karacal H, Rao PK. et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2018; 13: 53-55
    CrossrefPubMedGoogle Scholar
  • 10 Miserocchi E, Giuffrè C, Cornalba M. et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39: 847-851
    CrossrefPubMedGoogle Scholar